Beam Therapeutics (NASDAQ: BEAM)
Key Data Points
Beam Therapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Beam Therapeutics Company Info
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
News & Analysis
Why Beam Therapeutics Stock Zoomed 17% Higher Today
JPMorgan Chase becomes the latest institution in the company's bull pen.
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
Analysts have high hopes for these three innovation companies in 2024.
Is Beam Therapeutics Stock a Buy Now?
It has plenty of money, but it'll be facing plenty of competition, too.
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
Lilly is putting its money where its mouth is with cutting-edge medical technology.
5 Reasons Beam Therapeutics Remains a Risky Stock
Shares of the gene-editing biotech might not have hit rock bottom yet.
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
Some of the strategic shifts proposed by management are for the better.
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?
Beam Therapeutics' pipeline will look slimmer going forward.
Beam Therapeutics Stock: Bear vs. Bull
This biotech has a few factors in its corner, but it also faces a difficult path.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.